EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy of ANTHRASIL (Anthrax Immune Globulin Intravenous (Human)) in rabbit and nonhuman primate models of inhalational anthrax: Data supporting approval under animal rule

Srinivas Kammanadiminti iD, Jason Comer, Gabriel Meister, Trevor Carnelley, Derek Toth, Shantha Kodihalli iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0283164 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2023. Verfasst von Srinivas Kammanadiminti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Emergent BioSolutions Canada (Previously Cangene Corporation), Winnipeg, MB, Canada. Hauptthemen laut MEDLINE: Anthrax, Bacillus anthracis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biomedical Advanced Research and Development Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To meet the requirements of the Animal Rule, the efficacy of monotherapy with ANTHRASIL ® (Anthrax Immune Globulin Intravenous (Human)) for inhalational anthrax was evaluated in blinded studies using rabbit and nonhuman primate models. Animals in both studies were randomized to treatment groups exposed to ~ 200 LD 50 Bacillus anthracis (Ames strain) spores by the aerosol route to induce inhalational anthrax. Rabbits (N = 50/group) were treated with either 15 U/kg ANTHRASIL or a volume-matching dose of IGIV after disease onset as determined by the detection of bacterial toxin in the blood. At the end of the study, survival rates were 2% (1 of 48) in the IGIV control group, and 26% (13 of 50) in the ANTHRASIL-treated group (p = 0.0009). Similarly, ANTHRASIL was effective in cynomolgus monkeys (N = 16/group) when administered therapeutically after the onset of toxemia, with 6% survival in the IGIV control and a dose-related increase in survival of 36%, 43%, and 70% with 7.5, 15 or 30 U/kg doses of ANTHRASIL, respectively. These studies formed the basis for approval of ANTHRASIL by FDA under the Animal Rule.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnthraxBacillus anthracisRabbitsImmunoglobulin GAntigens, BacterialDisease Models, AnimalHumansPrimatesAnimalsAntitoxinsRespiratory Tract Infections

Substanzen

Immunoglobulin GAntigens, BacterialAnthrax Immune Globulin IntravenousAntitoxins

Autor:innen und Institutionen

  • Emergent BioSolutions Canada (Previously Cangene Corporation), Winnipeg, MB, Canada.
  • Battelle Biomedical Research Center, Columbus, Ohio, United States of America.

ORCID-Profile: Srinivas Kammanadiminti, Shantha Kodihalli

Förderung

  • Biomedical Advanced Research and Development Authority

Zitieren

APA

Kammanadiminti, S., Comer, J., Meister, G., Carnelley, T., Toth, D., & Kodihalli, S. (2023). Efficacy of ANTHRASIL (Anthrax Immune Globulin Intravenous (Human)) in rabbit and nonhuman primate models of inhalational anthrax: Data supporting approval under animal rule. PLOS ONE. https://doi.org/10.1371/journal.pone.0283164

Vancouver

Kammanadiminti S, Comer J, Meister G, Carnelley T, Toth D, Kodihalli S. Efficacy of ANTHRASIL (Anthrax Immune Globulin Intravenous (Human)) in rabbit and nonhuman primate models of inhalational anthrax: Data supporting approval under animal rule. PLOS ONE. 2023. doi:10.1371/journal.pone.0283164

BibTeX
@article{Kammanadiminti2023,
  author = {Kammanadiminti, Srinivas and Comer, Jason and Meister, Gabriel and Carnelley, Trevor and Toth, Derek and Kodihalli, Shantha},
  title = {Efficacy of ANTHRASIL (Anthrax Immune Globulin Intravenous (Human)) in rabbit and nonhuman primate models of inhalational anthrax: Data supporting approval under animal rule},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0283164}
}
Kostenlos starten →